Table 2

Comparison of pharmacokinetic parameters for human IFN-β-1a and PEGylated human IFN-β-1a in monkeys, rats, and mice following different routes of administration

Species	Route	Treatment	Dose	C_max	t_max	AUC	F	t_1/2
			MU/kg	U/ml	h	U × h/ml	%	h
Rat	i.v.	IFN-β-1a	21.9	117,433	0.00	83,951	NA	1.47
		PEG IFN-β-1a	3.3	24,000	0.00	170,397	NA	10.13
	i.p.	IFN-β-1a	22.1	26,000	1.25	82,736	98.6	1.46
		PEG IFN-β-1a	3.2	9,700	1.25	157,421	92.4	10.82
	s.c.	IFN-β-1a	21.7	2,400	1.00	9,911	11.8	1.47
		PEG IFN-β-1a	3.4	2,000	7.00	48,130	28.2	10.56
	i.t.	IFN-β-1a	18.0	240	1.50	1,160	1.4	1.49
		PEG IFN-β-1a	17.5	267	7.00	4,529	2.7	10.86
Monkey	i.v.	IFN-β-1a	1.0	6,400	0.083^2-a	4,453	NA	3.20
		PEG IFN-β-1a	1.0	10,800	0.083^2-a	34,373	NA	9.50
	s.c.	IFN-β-1a	1.0	277	5.30	4,753	107.0	10.00
		PEG IFN-β-1a	1.0	1,080	3.30	42,283	123.0	22.00
Mouse	i.v.	IFN-β-1a	2.6	113,708	0.00	10,653	NA	0.92
		PEG IFN-β-1a	2.6	143,524	0.00	140,598	NA	9.96

F, bioavailability; NA, not applicable.
↵2-a First time point measured.